Quantcast

Agenus, Inc. Checkpoint Modulators and Combination Therapies for Cancer - Valley News Live - KVLY/KXJB - Fargo/Grand Forks

Agenus, Inc. Checkpoint Modulators and Combination Therapies for Cancer

Posted: Updated:

PITTSBURGH, PA / May 15, 2014 / Agenus, Inc. (NASDAQ: AGEN) today published a new blog post on The Chairman’s Blog, written by 4-Antibody’s President, Robert F. Burns PhD. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

In his guest blog, Dr. Robert F. Burns reflects on the advancements made within the immuno-oncology field in recent years. He specifically focuses on the potential of checkpoint modulators (CPMs) and combination therapies as treatments for cancer. Dr. Burns writes, “[CPMs] have shown unprecedented efficacy and, presently, they constitute the most promising tools for successfully combating cancer.” Read the full blog post from Dr. Robert F. Burns on TheChairmansBlog.com (http://www.thechairmansblog.com/agenus/robert-burns/checkpoint-modulators-combination-therapies-cancer/)

About Agenus

Agenus is a biopharmaceutical company developing a portfolio of immuno-oncology candidates, including checkpoint modulators (CPMs), heat shock protein vaccines and adjuvants. The company’s proprietary discovery engine Retrocyte Display® is designed to rapidly generate high quality therapeutic antibody drug candidates using a high-throughput approach incorporating full-length IgG format human antibody libraries expressed in mammalian B-lineage cells. A portfolio of checkpoint modulator programs is advancing in preclinical development. The company’s heat shock protein vaccines for cancer and infectious disease are in Phase 2 studies. Agenus’ QS-21 Stimulon adjuvant platform is extensively partnered with GlaxoSmithKline and Janssen and includes several candidates in Phase 3 trials. Among Agenus and its partners, 23 programs are in clinical development. For more information, please visit www.agenusbio.com, or connect with the company on Facebook, LinkedIn, Twitter and Google+.

About TheChairmansBlog.com

TheChairmansBlog.com is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. www.thechairmansblog.com

SOURCE: The Chairmans Blog  

ReleaseID: 415686

Powered by WorldNow
Powered by 

WorldNowAll content © Copyright 2000 - 2014 WorldNow and Valley News Live. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.